Combating Antimicrobial Resistance: A Pharmacist’s and Physician’s Perspective on Stewardship

Antimicrobial resistance (AMR) poses a significant global health threat. Despite the existence of antimicrobial stewardship programs (ASPs), millions contract drug-resistant infections annually, with projections estimating a staggering 10 million deaths globally per year by 2050. This escalating crisis underscores the need for continued vigilance and innovative strategies to combat AMR, impacting morbidity, mortality, and healthcare costs.

Image credit: nobeastsofierce | stock.adobe.com

The primary driver of this resistance is the misuse of antimicrobial medications. Contributing factors include self-medication with antibiotics, widespread use in agriculture and livestock, and the contamination of water sources through sewage and industrial waste.

The Role of Antimicrobial Stewardship Programs (ASPs)

ASPs are crucial in optimizing antimicrobial use, improving patient outcomes, and mitigating the emergence of resistance. These programs are inherently multidisciplinary, involving infectious disease physicians, infection control specialists, epidemiologists, and pharmacists. Pharmacists play a vital role within ASPs, leveraging their expertise to perform essential duties, including improving prescribing practices, reducing unnecessary antibiotic use, optimizing antibiotic selection and therapy, and ultimately enhancing patient clinical outcomes.

While most ASPs operate within hospitals and clinics, community-based stewardship is equally critical. Community pharmacists contribute significantly by educating both healthcare professionals and patients, reviewing prescriptions for potential interactions and allergies, and recommending therapy de-escalation when appropriate.

Addressing Patient Concerns and Misconceptions

Community pharmacists often encounter patients resistant to a physician’s decision to withhold an antibiotic prescription. For example, some parents still expect antibiotics for their child’s ear infection, a practice now generally discouraged. Effective communication is key to addressing these concerns. Explaining the potential adverse effects of antibiotics, emphasizing the consequences of misuse, and highlighting the irreversible environmental impact can help patients understand the broader implications of overuse.

Antibiotic Adverse Events: A Real Risk

Antibiotics are notorious for causing adverse events (AEs), with over 30% of children experiencing AEs after 14 days or more of antibiotic use. While many AEs are mild and self-limiting, symptoms like diarrhea and rash can indicate the potential for more serious complications. Openly discussing the likelihood of AEs helps patients understand their personal risks. Common AEs include gastrointestinal issues, allergic reactions, and potential drug interactions.

Community pharmacists also contribute to stewardship by guiding patients on topical treatments. Over-the-counter topical antibiotics like bacitracin are often misused, carrying risks of allergy and anaphylaxis. Recommending simple wound care with mild soap, water, and plain petrolatum offers a safer and equally effective alternative.

Environmental Impact: A Growing Concern

Many patients are environmentally conscious, providing an opportunity to connect antimicrobial stewardship with environmental protection. Antibiotic metabolites and residues enter our water systems, impacting aquatic life, birds, and bees. Educating patients about the long-term ecological consequences of antibiotic overuse can motivate responsible use.

Conclusion: A Collaborative Approach

Pharmacists play a crucial role in promoting antimicrobial stewardship. Clear communication about potential AEs, appropriate antibiotic use, and environmental impact empowers patients to make informed decisions. While stewardship is a multidisciplinary effort, pharmacists are uniquely positioned to initiate and facilitate these essential conversations, contributing to a healthier future for individuals and the planet. Consult with a healthcare professional for personalized treatment plans and guidance on responsible antibiotic use.

References

1. Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903-3910.
2. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-318.
3. Antimicrobial resistance. World Health Organization. November 21, 2023. Accessed January 20, 2024. http://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
4. Rather IA, Kim BC, Bajpai VK, Park YH. Self-medication and antibiotic resistance: crisis, current challenges, and prevention. Saudi J Biol Sci. 2017;24(4):808-812.
5. Hashemi S, Nasrollah A, Rajabi M. Irrational antibiotic prescribing: a local issue or global concern? EXCLI J. 2013;12:384-395.
6. Timbrook TT, Hurst JM, Bosso JA. Impact of an antimicrobial stewardship program on antimicrobial utilization, bacterial susceptibilities, and financial expenditures at an academic medical center. Hosp Pharm. 2016;51(9):703-711.
7. Zay Ya K, Win PTN, Bielicki J, Lambiris M, Fink G. Association between antimicrobial stewardship programs and antibiotic use globally: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(2):e2253806.
8. Dighriri IM, Alnomci BA, Aljahdali MM, et al. The role of clinical pharmacists in antimicrobial stewardship programs (ASPs): a systematic review. Cureus. 2023;15(12):e50151.
9. Otieno PA, Campbell S, Maley S, Obinju Arunga T, Otieno Okumo M. A systematic review of pharmacist-led antimicrobial stewardship programs in sub-Saharan Africa. Int J Clin Pract. 2022;2022:3639943.
10. Suh Y, Ah YM, Chun HJ, et al. Potential impact of the involvement of clinical pharmacists in antimicrobial stewardship programs on the incidence of antimicrobial-related adverse events in hospitalized patients: a multicenter retrospective study. Antibiotics (Basel). 2021;10(7):853.
11. Hammond KM, Kabbani D, Doucette KE, et al. How does the antimicrobial stewardship provider role affect prospective audit and feedback acceptance for restricted antibiotics in a Canadian tertiary-care center? Infect Control Hosp Epidemiol. Published online August 18, 2023.
12. Palanisamy PR. Stop antibiotic resistance – a roller coaster ride through “antibiotic stewardship,” “prescription auditing” and “AWaRe” assessment tool. J Family Med Prim Care. 2023;12(9):1796-1801.
13. Olson SC, Smith S, Weissman SJ, Kronman MP. Adverse events in pediatric patients receiving long-term outpatient antimicrobials. J Pediatric Infect Dis Soc. 2015;4(2):119-125.
14. Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44(5):161-164.
15. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404-1410.
16. Barbut F, Meynard JL. Managing antibiotic-associated diarrhoea. BMJ. 2002;324(7350):1345-1346.
17. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334-339.
18. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969.
19. Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020;27(1):31-37.
20. Kim SY, Moon A. Drug-induced nephrotoxicity and its biomarkers. Biomol Ther (Seoul). 2012;20(3):268-272.
21. Perazella MA, Rosner MH. Drug-induced acute kidney injury. Clin J Am Soc Nephrol. 2022;17(8):1220-1233.
22. Smith CA. Trimethoprim-sulfamethoxazole and hyperkalemia. Nephrol Nurs J. 2021;48(2):177-180.
23. Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Am J Nephrol. 1999;19(3):389-394.
24. Mowad CM. Contact allergens of the year. Adv Dermatol. 2004;20:237-255.
25. Sood A, Taylor JS. Bacitracin: allergen of the year. Am J Contact Dermat. 2003;14(1):3-4.
26. Spring S, Pratt M, Chaplin A. Contact dermatitis to topical medicaments: a retrospective chart review from the Ottawa Hospital Patch Test Clinic. Dermatitis. 2012;23(5):210-213.
27. Wang K, Zhuang T, Su Z, Chi M, Wang H. Antibiotic residues in wastewaters from sewage treatment plants and pharmaceutical industries: occurrence, removal and environmental impacts. Sci Total Environ. 2021;788:147811.